Ownership Submission
FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Meyers James R
 2. Date of Event Requiring Statement (Month/Day/Year)
11/10/2016		 3. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES INC [GILD]
(Last)
(First)
(Middle)
GILEAD SCIENCES, INC., 333 LAKESIDE DRIVE		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
EVP Worldwide Commercial Ops
 5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

FOSTER CITY, CA 94404		 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 6,726
D
 
Common Stock 121,151
I
By Trust

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Non-qualified Stock Option (Right to Buy)   (3) 10/22/2017 Common Stock 60,000 $ 21 D  
Non-qualified Stock Option (Right to Buy)   (3) 01/30/2018 Common Stock 100,000 $ 21.575 D  
Non-qualified Stock Option (Right to Buy)   (3) 01/21/2019 Common Stock 60,000 $ 23.6 D  
Non-qualified Stock Option (Right to Buy)   (3) 07/29/2019 Common Stock 60,000 $ 24.905 D  
Non-qualified Stock Option (Right to Buy)   (3) 01/28/2020 Common Stock 53,200 $ 23.755 D  
Non-qualified Stock Option (Right to Buy)   (4) 01/20/2021 Common Stock 67,200 $ 19.085 D  
Non-qualified Stock Option (Right to Buy)   (4) 01/26/2022 Common Stock 48,000 $ 24.295 D  
Non-qualified Stock Option (Right to Buy)   (4) 02/01/2023 Common Stock 34,890 $ 40.56 D  
Non-qualified Stock Option (Right to Buy)   (4) 02/01/2024 Common Stock 25,780 $ 80.65 D  
Non-qualified Stock Option (Right to Buy)   (4) 02/01/2025 Common Stock 17,590 $ 104.83 D  
Non-qualified Stock Option (Right to Buy)   (4) 02/01/2026 Common Stock 17,560 $ 84.05 D  
Non-qualified Stock Option (Right to Buy)   (4) 08/10/2026 Common Stock 15,450 $ 78.9 D  
Restricted Stock Unit   (2)   (2) Common Stock 9,780 $ (1) D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Meyers James R
GILEAD SCIENCES, INC.
333 LAKESIDE DRIVE
FOSTER CITY, CA 94404		       EVP Worldwide Commercial Ops  

Signatures

/s/ Marissa Song by Power of Attorney for James R. Meyers 11/21/2016
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
(2) The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested.
(3) The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested.
(4) The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.